机译:Myelodysplastic综合征中的口服VEGF受体酪氨酸激酶抑制剂Vatalanib(PTK787 / ZK222584)的II期研究:癌症和白血病组研究10105(联盟)
University of Minnesota Minneapolis MN United States Hematology/Oncology Section 111E;
Alliance Statistics and Data Center Duke University Medical Center Durham NC United States;
Massachusetts General Hospital Boston MA United States;
Alliance Statistics and Data Center Duke University Medical Center Durham NC United States;
Washington University in St. Louis St. Louis MO United States;
Wake Forest University Winston-Salem NC United States;
University of Chicago Chicago IL United States;
Ohio State University Columbus OH United States;
Alliance Statistics and Data Center Duke University Medical Center Durham NC United States;
Dana-Farber Cancer Institute Boston MA United States;
University of Chicago Chicago IL United States;
(MeSH): Angiogenesis inhibitors; Humans; Myelodysplastic syndromes; Treatment outcome; Vascular endothelial growth factor;
机译:口服VEGF受体酪氨酸激酶抑制剂vatalanib(PTK787 / ZK222584)在骨髓增生异常综合症的II期研究:癌症和白血病B组研究10105(联盟)
机译:在晚期实体瘤患者中,将mToR抑制剂依维莫司(RAD001)与两种时间表的血管内皮生长因子(VEGF)酪氨酸激酶抑制剂Vatalanib(PTK787 / ZK222584)组合使用的POSTER A I期试验
机译:成人难治性或复发性弥漫性大B细胞淋巴瘤患者口服血管内皮生长因子受体抑制剂PTK787 / ZK222584(vatalanib)的II期开放标签研究
机译:用Toceranib治疗的猫的探索性安全性和毒物动力学研究,口服酪氨酸激酶激酶抑制剂
机译:多靶点受体酪氨酸激酶抑制剂利尼法尼(ABT-869)通过磷酸肌醇3激酶(PI3K)/ AKT依赖性信号传导途径诱导凋亡并抑制白血病细胞的增殖。
机译:骨髓增生异常综合症中口服VEGF受体酪氨酸激酶抑制剂Vatalanib(PTK787 / ZK222584)的II期研究:癌症和白血病B组研究10105(联盟)
机译:Myelodysplastic综合征中的口服VEGF受体酪氨酸激酶抑制剂Vatalanib(PTK787 / ZK222584)的II期研究:癌症和白血病组研究10105(联盟)